MODIFICATION
Q -- DNA gene mutation services for the Inherited Bone Marrow Failure Syndromes (IBMFS) Cohort
- Notice Date
- 8/30/2010
- Notice Type
- Modification/Amendment
- NAICS
- 621511
— Medical Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-100213-AV
- Archive Date
- 9/22/2010
- Point of Contact
- Ashley L. Virts,
- E-Mail Address
-
virtsa@mail.nih.gov
(virtsa@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Clinical Genetics Branch (CGB) plans to procure on a sole source basis with Ambry Genetics; 100 Columbia, Suite 200; Aliso Viejo, California 92656-4114 for clinical grade sequencing services on the nine known Inherited Bone Marrow Failure Syndromes IBMFS genes from patient DNA samples. The supplies and services herein are commercial as defined in FAR Part 12, and this acquisition is being made in accordance with the test program for using simplified procedures for certain commercial items as authorized in FAR Part 13.5. The North American Industry Classification System code is 621511 and the business size standard is $12.5M. Period of Performance shall be for twelve (12) months from award, with two (4) twelve month option periods. In addition, this is a firm fixed price, indefinite delivery/indefinite quantity (IDIQ) type contract. Only one (1) award will be made as a result of this notice. The (IBMFS) Cohort is a natural history study, focused on genotype/phenotype/cancer associations with cancer-prone rare genetic blood disorders. Diamond-Blackfan anemia (DBA) is one of the IBMFS; it is an autosomal dominant disorder in which mutated genes are involved in ribosomal biogenesis. There are nine genes identified to date, which account for about 50% of the patients. Dyskeratosis congenita (DC) is another of the IBMFS, for which there are six identified genes, also responsible for about half the patients. The Contractor shall provide clinical grade sequencing of the following IBMFS genes in order of their reported frequencies: DBA DC SDS Gene Frequency, % Gene Frequency, % Gene Frequency, % RPS19 25 DKC1 (XLR) 30% of males SBDS (AR) 90-95 RPL5 7 TERC (AD) 10 RPS26 6 TERT (AD, AR) 5 RPL11 5 TINF2 (AD) 10-20 RPL35A 3.5 NOLA2 (AR) 1 RPS10 3 NOLA3 (AR) 1 RPS24 2 RPS17 1 RPS7 1 The Government will provide the Contractor with DNA samples (5-20 ug) from a maximum of 50 samples per year. Samples shall be sent to the Contractor in batches, representing family groups, syndrome groups or individuals. Each sample will be recorded separately to include a description of the specimen, the method used and the region(s) of the gene that were analyzed. The contractor must be CLIA-certified, and must have established the sequencing approach for each gene using standard methods. The contractor must be able to sequence all exons and intron/exon boundaries in each gene and be able to expand their IBMFS platform to include new genes as they are identified, or establish alternative methods for sequencing as they evolve, including regulatory regions of the genes. Ambry Genetics is the only source known to the NCI that can provide gene mutation services on all available genes for DBA, DC, and SDS. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on September 7, 2010. No electronic capability statements will be accepted (i.e. email or fax), an original and one copy must be sent to the NCI Office of Acquisitions to the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Ashley Virts, Contract Specialist at virtsa@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-100213-AV on all correspondences.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-100213-AV/listing.html)
- Record
- SN02260830-W 20100901/100830235630-389659977ef041467390ed3c64da474d (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |